A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered."

"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered."